A Phase 2A , Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Dose Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Doses of MEDI-545, A Fully Human Anti-Interferon-Alpha Monoclonal Antibody, In Subjects With Systemic Lupus Erythematosus

Trial Profile

A Phase 2A , Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Dose Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Doses of MEDI-545, A Fully Human Anti-Interferon-Alpha Monoclonal Antibody, In Subjects With Systemic Lupus Erythematosus

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2016

At a glance

  • Drugs Sifalimumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Jul 2012 Actual end date changed from 1 Aug 2010 to 1 Jul 2010 as reported by ClinicalTrials.gov.
    • 11 Jul 2012 Actual initiation date changed from 1 May 2008 to 1 Aug 2008 as reported by ClinicalTrials.gov.
    • 28 May 2011 Pharmacokinetic results presented at the 12th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top